芩香清解口服液联合利巴韦林治疗儿童上呼吸道感染的临床研究
|
摘要
目的探讨芩香清解口服液联合利巴韦林注射液治疗儿童上呼吸道感染的临床疗效。方法选取2017年7月—2018年9月新乡医学院第一附属医院收治的上呼吸道感染患儿114例作为研究对象,将患儿根据随机数字表法分为对照组和治疗组,每组各57例。对照组静脉滴注利巴韦林注射液,10mg/kg加入到100m L葡萄糖注射液中充分稀释,1次/d。治疗组在对照组的基础上口服芩香清解口服液,10 mL/次,3次/d。两组患儿均治疗3 d。观察两组患儿的临床疗效,同时比较两组治疗前后的临床症状改善时间和炎症因子水平。结果治疗后,治疗组的总有效率为92.98%,显著高于对照组的78.95%,两组比较差异具有统计学意义(P<0.05)。治疗后,治疗组的退热时间、止咳时间、咽痛消失时间、止涕时间均显著短于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组超敏C反应蛋白(hs-CRP)、肿瘤坏死因子α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-4(IL-4)水平均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组炎症因子水平明显低于对照组,两组比较差异具有统计学意义(P<0.05)。结论芩香清解口服液联合利巴韦林注射液能提高儿童上呼吸道感染的疗效,降低血清炎症因子水平,具有一定的临床推广应用价值。
Objective To investigate the clinical efficacy of Qinxiang Qingjie Oral Liquid combined with Ribavirin Injection in treatment of children upper respiratory tract infection. Methods Children(114 cases) with upper respiratory tract infection in the First Affiliated Hospital of Xinxiang Medical University from July 2017 to September 2018 were randomly divided into control and treatment groups, and each group had 57 cases. Children in the control group were iv administered with Ribavirin Injection, 10 mg/kg added into glucose injection 100 mL, once daily. Children in the treatment group were po administered with Qinxiang Qingjie Oral Liquid 10 mL/time, three times daily. Children in two groups were treated for 3 d. After treatment, the clinical efficacy was evaluated, the improvement time of clinical symptoms and inflammatory factor levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the treatment group was 92.98%, which was significantly higher than 78.95% in the control group, there were differences between two groups(P < 0.05). After treatment, times of defervescence, cough relief, pharyngalgia disappearance, and runny nose relief in the treatment group were significantly shorter than those in the control group, and there were differences between two groups(P < 0.05). After treatment, hs-CRP, TNF-α, IL-6, and IL-4 levels in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, inflammatory factors levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Qinxiang Qingjie Oral Liquid combined with Ribavirin Injection can improve the efficacy of children upper respiratory tract infection, and reduce the level of serum inflammatory factors, which has a certain clinical application value.
Objective To investigate the clinical efficacy of Qinxiang Qingjie Oral Liquid combined with Ribavirin Injection in treatment of children upper respiratory tract infection. Methods Children(114 cases) with upper respiratory tract infection in the First Affiliated Hospital of Xinxiang Medical University from July 2017 to September 2018 were randomly divided into control and treatment groups, and each group had 57 cases. Children in the control group were iv administered with Ribavirin Injection, 10 mg/kg added into glucose injection 100 mL, once daily. Children in the treatment group were po administered with Qinxiang Qingjie Oral Liquid 10 mL/time, three times daily. Children in two groups were treated for 3 d. After treatment, the clinical efficacy was evaluated, the improvement time of clinical symptoms and inflammatory factor levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the treatment group was 92.98%, which was significantly higher than 78.95% in the control group, there were differences between two groups(P < 0.05). After treatment, times of defervescence, cough relief, pharyngalgia disappearance, and runny nose relief in the treatment group were significantly shorter than those in the control group, and there were differences between two groups(P < 0.05). After treatment, hs-CRP, TNF-α, IL-6, and IL-4 levels in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, inflammatory factors levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Qinxiang Qingjie Oral Liquid combined with Ribavirin Injection can improve the efficacy of children upper respiratory tract infection, and reduce the level of serum inflammatory factors, which has a certain clinical application value.
引文
[1]中华中医药学会儿科分会临床评价学组.小儿急性上呼吸道感染中药新药临床试验设计与评价技术指南[J].药物评价研究, 2015, 38(1):8-16.
[2]张帆.利巴韦林与热毒宁治疗小儿急性上呼吸道感染[J].吉林中医药, 2017, 37(7):670-673.
[3]李井锋,马融,胡思源,等.芩香清解口服液治疗小儿急性上呼吸道感染表里俱热证的多中心临床研究[J].中华中医药杂志, 2015, 30(10):3794-3796.
[4]葛均波,徐永健.内科学.第8版[M].北京:人民卫生出版社, 2013:13-15.
[5]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社, 2002:58-61.
[6]胡春芳,黄胜兰,王代宏,等.小儿上呼吸道感染病原菌分析及血清炎症因子的辅助诊断价值[J].中华医院感染学杂志, 2017, 27(17):4008-4011.
[7]魏丽娜,吴力群.小儿上呼吸道病毒感染与中医证候相关性研究[J].中国妇幼保健,2018,33(8):1804-1805.
[8]胡思源,马融,陈馨雨,等.芩香清解口服液治疗小儿急性上呼吸道感染表里俱热证的多中心Ⅲ期临床研究[J].中国新药杂志, 2017, 26(10):1152-1156.
[9]李小红.小儿急性上呼吸道感染患儿C反应蛋白、前白蛋白、白细胞的变化分析[J].实用临床医药杂志,2015, 19(19):194-195.
[10]毕永春,罗浔阳,李玉麒,等.CRP与血常规联合检测在儿科急性上呼吸道感染诊断中的应用[J].中国实验诊断学, 2016, 20(10):1738-1740.
[11]闫学平,郝秀丽,孙婷,等.血常规联合hs-CRP、免疫学指标检测在儿童急性上呼吸道感染中的临床价值[J].现代生物医学进展, 2018, 23(8):1502-1505.
[12]李春,叶梅. 0~3岁反复上呼吸道感染患儿血清细胞因子IL-6、IL-10和TNF-α的水平及意义[J].河北医药, 2017, 39(1):14-16.
[13]李大登,魏小妹.血清降钙素原、超敏C反应蛋白及白细胞介素-6在小儿急性上呼吸道感染中的诊断价值[J].微循环学杂志, 2014, 24(2):61-63.
[14]迟作华,刘振,肖平. NK细胞及IL-2、IL-4、IFN-γ在上呼吸道感染诱发急性分泌性中耳炎患者的表达[J].中国实验诊断学, 2014, 18(6):973-975.
[2]张帆.利巴韦林与热毒宁治疗小儿急性上呼吸道感染[J].吉林中医药, 2017, 37(7):670-673.
[3]李井锋,马融,胡思源,等.芩香清解口服液治疗小儿急性上呼吸道感染表里俱热证的多中心临床研究[J].中华中医药杂志, 2015, 30(10):3794-3796.
[4]葛均波,徐永健.内科学.第8版[M].北京:人民卫生出版社, 2013:13-15.
[5]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社, 2002:58-61.
[6]胡春芳,黄胜兰,王代宏,等.小儿上呼吸道感染病原菌分析及血清炎症因子的辅助诊断价值[J].中华医院感染学杂志, 2017, 27(17):4008-4011.
[7]魏丽娜,吴力群.小儿上呼吸道病毒感染与中医证候相关性研究[J].中国妇幼保健,2018,33(8):1804-1805.
[8]胡思源,马融,陈馨雨,等.芩香清解口服液治疗小儿急性上呼吸道感染表里俱热证的多中心Ⅲ期临床研究[J].中国新药杂志, 2017, 26(10):1152-1156.
[9]李小红.小儿急性上呼吸道感染患儿C反应蛋白、前白蛋白、白细胞的变化分析[J].实用临床医药杂志,2015, 19(19):194-195.
[10]毕永春,罗浔阳,李玉麒,等.CRP与血常规联合检测在儿科急性上呼吸道感染诊断中的应用[J].中国实验诊断学, 2016, 20(10):1738-1740.
[11]闫学平,郝秀丽,孙婷,等.血常规联合hs-CRP、免疫学指标检测在儿童急性上呼吸道感染中的临床价值[J].现代生物医学进展, 2018, 23(8):1502-1505.
[12]李春,叶梅. 0~3岁反复上呼吸道感染患儿血清细胞因子IL-6、IL-10和TNF-α的水平及意义[J].河北医药, 2017, 39(1):14-16.
[13]李大登,魏小妹.血清降钙素原、超敏C反应蛋白及白细胞介素-6在小儿急性上呼吸道感染中的诊断价值[J].微循环学杂志, 2014, 24(2):61-63.
[14]迟作华,刘振,肖平. NK细胞及IL-2、IL-4、IFN-γ在上呼吸道感染诱发急性分泌性中耳炎患者的表达[J].中国实验诊断学, 2014, 18(6):973-975.